case_images: PMC7708326_01
case_images: Timeline of disease progression and treatment.
case_images: fendo-11-576027-g001.jpg
case_images: PMC7708326_01_fendo-11-576027-g001.jpg
case_images: f1
case_images: A 72 year old female was diagnosed with a silent lactotroph pituitary carcinoma in August 2018 ( Figure 1 ).
case_images: MRI pituitary, sagittal views. (A) October 2018 prior to dual ICI therapy, (B) June 2019 demonstrating response to dual ICI therapy, (C) September 2019 demonstrating progressive disease, (D) December 2019 demonstrating progressive disease following repeat dual ICI therapy, (E) April 2020 demonstrating stable disease following bevacizumab. (A-D) T1 weighted images post gadolinium, (E) T2 weighted images without gadolinium due to renal impairment.
case_images: fendo-11-576027-g002.jpg
case_images: PMC7708326_01_fendo-11-576027-g002.jpg
case_images: f2
case_images: There was a marked clinical and radiological response of the primary pituitary carcinoma and all metastatic lesions that was sustained for eight months ( Figures 2  and  3 ).
case_images: Pituitary carcinoma size (mm) over time. Superior to inferior measurement (SI), Anterior to posterior measurement (AP).
case_images: fendo-11-576027-g003.jpg
case_images: PMC7708326_01_fendo-11-576027-g003.jpg
case_images: f3
case_images: There was a marked clinical and radiological response of the primary pituitary carcinoma and all metastatic lesions that was sustained for eight months ( Figures 2  and  3 ).